Omnicell's Gross Margin Climbs To 45% On Lapping Last Year's Service Costs, Not Product Strength
Product revenue fell $4.4 million and chip costs lifted product costs, while a one-off service cost from 2025 flattered the comparison.
Omnicell's third-quarter gross margin rose to 45% from 43%, but the company's 10-Q credits the gain to non-recurring service costs, including software upgrade expenses, that hit a year earlier. Product costs rose on higher semiconductor chip prices as product revenue fell.
Service savings carry the margin
Omnicell, which makes medication management systems that hospitals and pharmacies use to store, dispense and track drugs, cut its cost of service revenues to $71.8 million from $79.4 million. The filing attributes the drop to the non-recurring costs incurred in the third quarter of 2025.
Service cost fell to 53% of service revenue from 60%. Gross profit rose to $137.8 million from $134.5 million, on total revenue of $307.9 million, down 1% from $310.6 million.
Net income was $11.0 million, or $0.24 per diluted share, against $5.5 million, or $0.12, a year earlier.
Chips and a missing tariff refund
Product cost rose to 57% of product revenue from 55%. The filing ties the increase to higher chip costs, along with the decline in product revenue.
The $4.4 million product revenue drop came mostly from weaker XTExtend volumes, with XT Series automated dispensing systems offsetting part of it. For the nine months, product revenue was up $37.1 million.
In the second quarter, product cost was helped by a $14.0 million refund of tariffs struck down by the Supreme Court. That benefit is absent now, and the company says it does not expect further refunds to be material.
Section 232 tariff review looms
The 10-Q adds language that the U.S. government is conducting or has conducted Section 232 investigations covering medical equipment and devices, which could bring additional tariffs or import limits on products or components Omnicell imports.
The company said it does not expect recent tariff changes to have a material impact. It also holds $314.9 million in cash and has no balance drawn on its $350.0 million revolving credit facility. Its market value was $1.6 billion in Wednesday trading.
Remaining performance obligations not yet in deferred revenue stood at $375.1 million at September 30, 2026.
Sources
- 10-Q Filing — Omnicell (OMCL) — SEC EDGAR
- 10-Q Filing — Omnicell (OMCL), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, exhibit991q3-26.htm) — Omnicell, filed 2026-10-29 — SEC EDGAR
- OMCL Q3 deep dive: disciplined cost control offsets flat sales, software transition in early innings — Yahoo Finance
- Omnicell’s Q3 earnings call: our top 5 analyst questions — Yahoo Finance
- Omnicell, Inc. (OMCL) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance
- Omnicell Inc. (NASDAQ:OMCL) : Articles :: Law360 — law360.com
- Inside the 1st-year priorities of a new pharmacy director - Becker's Hospital Review — beckershospitalreview.com